Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
FRACTION-RCC: Evaluating nivolumab plus ipilimumab in patients with treatment-refractory advance...
Front-line therapy with nivolumab and salvage nivolumab + ipilimumab in patients with advanced RCC
Nivolumab With or Without Ipilimumab in Gastroesophageal Junction Cancer
Targeting Cancer Pathways: Understanding Immune Checkpoints
Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Approvals and indications
Identifying patients most likely to respond
Clinical trial history